[{"Assets_0_Q3_USD":1557300000.0,"CommonStockSharesOutstanding_0_Q3_shares":73400000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":52200000.0,"NetIncomeLoss_1_Q3_USD":6900000.0,"NetIncomeLoss_3_Q3_USD":8800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":73300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":73500000.0,"StockholdersEquity_0_Q3_USD":1081800000.0,"EarningsPerShareBasic_1_Q3_USD":0.09,"EarningsPerShareBasic_3_Q3_USD":0.12,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20190331","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20190508"}]